在美国就药品价格问题致函医药企业后，诺华制药股价在欧盘下跌1.2%；罗氏股价下跌1.9%。 ...

Core Insights - Roche announced five-year efficacy, safety, and durability data for Susvimo® (ranibizumab injection) in treating neovascular age-related macular degeneration (nAMD), showing sustained treatment effects with approximately 95% of patients requiring no supplemental treatment before each refill [1][6]. Efficacy and Safety Data - The Phase III Portal study demonstrated that Susvimo maintained vision and retinal drying over five years, with best-corrected visual acuity (BCVA) in the Susvimo cohort decreasing from 74.4 letters at baseline to 67.6 letters at five years, while the IVT-Susvimo cohort showed a decrease from 76.3 letters to 68.6 letters [3][6]. - Average central subfield thickness (CST) remained stable, with a reduction of 1.0 µm in the Susvimo cohort and 10.3 µm in the IVT-Susvimo cohort [3]. Study Design and Population - The Portal study followed a cohort of 352 patients, with 220 receiving Susvimo refills every six months and 132 transitioning from monthly intravitreal (IVT) injections to Susvimo [2][5]. - The Archway study, which preceded the Portal study, was a randomized, multicenter trial involving 415 patients, comparing Susvimo to monthly IVT ranibizumab injections [5]. Treatment Mechanism - Susvimo utilizes a refillable eye implant that continuously delivers a customized formulation of ranibizumab, contrasting with other treatments that may require monthly injections [4][9]. - This delivery system aims to provide a more consistent treatment regimen, potentially leading to better real-world outcomes for patients with nAMD [2][4]. Industry Context - nAMD is the leading cause of vision loss in individuals over 60, affecting approximately 20 million people globally, with numbers expected to rise as the population ages [8]. - The innovative approach of Susvimo positions Roche as a leader in the treatment of nAMD, addressing a significant unmet need in the market [6][9].

Core Insights - Roche announced five-year efficacy, safety, and durability data for Susvimo® (ranibizumab injection) in treating neovascular age-related macular degeneration (nAMD), showing sustained treatment effects with approximately 95% of patients requiring no supplemental treatment before each refill [1][2][7] Group 1: Study Results - The Phase III Portal study demonstrated that Susvimo maintained vision and retinal drying over five years, with best-corrected visual acuity (BCVA) showing a decline from 74.4 letters at baseline to 67.6 letters at five years in the Susvimo cohort, and from 76.3 letters to 68.6 letters in the IVT-Susvimo cohort [3][4] - Average central subfield thickness (CST) remained stable, with a reduction of 1.0 µm in the Susvimo cohort and 10.3 µm in the IVT-Susvimo cohort [3] Group 2: Treatment Comparison - Susvimo provides continuous delivery of ranibizumab via a refillable eye implant, contrasting with other treatments that may require monthly injections [5][10] - The Portal study cohort is the largest group of nAMD patients followed prospectively for five years, enhancing the reliability of the results [4][6] Group 3: Clinical Implications - The long-term results support Susvimo's potential to preserve vision in nAMD patients, addressing the challenges of frequent injections associated with traditional anti-VEGF treatments [2][7] - The study's findings may lead to improved real-world clinical outcomes for patients with nAMD, as continuous delivery could offer better vision preservation compared to standard treatments [2][6]

Why has Switzerland been hit so hard. So this came as a complete surprise to the Swiss. The reason for this is Switzerland's great huge surplus with the US.If you ranked the US trade deficits with other countries, the Switzerland ranks number 12. It's a $38 billion. So that obviously is a big number and that's mostly due to pharma.We know that pharma is one of the things that Trump targets. And Switzerland's just got the short end of the stick here. So what has been the response of the Swiss government. The ...

近日，美国食品药品管理局（FDA）调查结果显示，一名八岁男童的死亡事故与Sarepta的基因疗法"无 关"。 （文章来源：华尔街见闻） 罗氏制药将恢复在美国市场之外的基因疗法Elevidys发货工作。 ...

罗氏制药将恢复在美国市场之外的基因疗法Elevidys发货工作。 近日，美国食品药品管理局（FDA）调查结果显示，一名八岁男童的死亡事故与Sarepta的基因疗法"无 关"。 ...

罗氏将恢复美国以外地区的基因疗法Elevidys的发货。 ...

ARCALYST Performance and Market - ARCALYST has generated over $1 billion in revenue since its launch[7] - Expected 2025 ARCALYST revenue is projected to be between $625 million and $640 million[7, 51] - ARCALYST has achieved approximately 15% penetration into the target population of recurrent pericarditis patients as of Q2 2025[7, 23, 29] - Approximately 80% of ARCALYST prescriptions are for patients with ≥3rd recurrence[23] - Approximately 20% of ARCALYST prescriptions are for patients in their 1st recurrence[23] - Payer approval for ARCALYST exceeds 90% of completed cases[28] - Approximately 45% of patients restarted ARCALYST therapy following initial discontinuation within ~8 weeks[37, 40] - The average total duration of ARCALYST therapy is approximately 30 months[28, 40] Financial Position - Kiniksa reported Q2 2025 cash reserves of approximately $308 million[8] - Kiniksa's operating plan is expected to remain cash flow positive on an annual basis[7, 78] - ARCALYST net sales for Q2 2025 were $156.8 million, compared to $103.4 million in Q2 2024[77] KPL-387 Development - A Phase 2/3 trial for KPL-387 in recurrent pericarditis has been initiated, with Phase 2 dose-focusing data expected in the second half of 2026[8]

Core Viewpoint - AbbVie has submitted a supplemental New Drug Application (sNDA) to the FDA for a fixed-duration, all-oral combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL), potentially offering a new treatment option with time-limited therapy [1][2]. Group 1: Clinical Trial Results - The submission is based on positive results from the Phase 3 AMPLIFY trial, which demonstrated that the combination of VENCLEXTA and acalabrutinib improved progression-free survival (PFS) compared to standard chemoimmunotherapy in previously untreated CLL patients [2][3]. - The AMPLIFY trial showed a 35% reduction in the risk of disease progression or death with the fixed-duration combination regimen compared to chemoimmunotherapy (HR 0.65; 95% CI: 0.49-0.87; p=0.004) [3]. Group 2: Safety Profile - The safety profile of the VENCLEXTA and acalabrutinib combination is consistent with the known safety profiles of each therapy alone, with common adverse events including neutropenia, hemorrhage, and COVID-19 [3]. - Neutropenia was the most frequent Grade 3 or higher adverse event, occurring in 26.8% of patients, while low rates of tumor lysis syndrome were observed at 0.3% for the combination compared to 3.1% for chemoimmunotherapy [3]. Group 3: Product Information - VENCLEXTA (venetoclax) is a first-in-class medication that selectively inhibits the B-cell lymphoma-2 (BCL-2) protein, which is involved in preventing cancer cell apoptosis [4]. - VENCLEXTA is developed by AbbVie and Roche, and is approved in over 80 countries, including the U.S., with ongoing research into its use across various blood cancers [5]. Group 4: Company Commitment - AbbVie is dedicated to transforming cancer care through a dynamic pipeline of investigational therapies targeting various cancer types, focusing on creating targeted medicines to impede cancer cell reproduction or enable their elimination [23][25].

Core Insights - Roche is presenting new data from its Alzheimer's development portfolio at the Alzheimer's Association International Conference (AAIC) in Toronto, showcasing a comprehensive approach to address Alzheimer's disease across the patient journey [1][2]. Pharmaceuticals - The Phase Ib/IIa Brainshuttle™ AD study shows rapid and robust reduction of amyloid plaques, with 91% of participants in the 3.6 mg/kg cohort becoming amyloid PET negative after 28 weeks [6][7]. - Roche plans to initiate Phase III TRONTIER 1 and 2 studies later this year to investigate the efficacy and safety of trontinemab in early symptomatic Alzheimer's disease, with primary endpoints focusing on cognition and function after 18 months of treatment [5][6]. - An additional Phase III trial will investigate trontinemab in preclinical Alzheimer's disease, targeting individuals at risk of cognitive decline [2][3]. Diagnostics - Roche's Elecsys® pTau217 test is highlighted as a reliable blood-based biomarker for diagnosing amyloid pathology, showing comparable results to PET scans and CSF diagnostics [3][4]. - The test aims to improve patient access and reduce the time to definitive diagnosis, addressing the fact that up to 75% of individuals with Alzheimer's symptoms remain undiagnosed [4][10]. - New studies indicate that the Elecsys pTau217 test can be scaled for routine clinical practice, potentially transforming the diagnostic pathway for Alzheimer's disease [9][10]. Company Overview - Roche has over two decades of research in Alzheimer's disease, focusing on early detection and treatment to slow or prevent disease progression [16]. - The company combines its pharmaceutical and diagnostic capabilities to address the global challenges of Alzheimer's disease, emphasizing collaboration within the healthcare community [16].